Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Refractory CancerMetastatic Solid TumorSolid Tumor, Adult
- Interventions
- Drug: ADU-1805Drug: Pembrolizumab
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Sairopa B.V.
- Target Recruit Count
- 90
- Registration Number
- NCT05856981
- Locations
- 🇺🇸
Gabrail Cancer & Research Center, Canton, Ohio, United States
🇲🇩National Institute of Oncology, Chișinău, Moldova, Republic of
🇺🇸Carolina BioOncology Institute - Cancer Research Clinic, Huntersville, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath